Louis Moore Bacon's CYTK Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 25,000 shares of Cytokinetics, Incorporated (CYTK) worth $1.59 M, representing 0.02% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Louis Moore Bacon has maintained a strategic position in CYTK, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2021, adding 100,000 shares. Largest reduction occurred in Q3 2017, reducing 50,000 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Cytokinetics Incorporated (CYTK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytokinetics Incorporated (CYTK) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2025 | -10,000 | Reduce 28.57% | 25,000 | $54.96 |
| Q1 2024 | +30,000 | Add 600.00% | 35,000 | $70.11 |
| Q4 2023 | -20,000 | Reduce 80.00% | 5,000 | $83.49 |
| Q3 2022 | -25,000 | Reduce 50.00% | 25,000 | $48.44 |
| Q2 2022 | -25,000 | Reduce 33.33% | 50,000 | $39.30 |
| Q1 2022 | -25,000 | Reduce 25.00% | 75,000 | $36.81 |
| Q4 2021 | +100,000 | New Buy | 100,000 | $45.58 |
| Q4 2020 | -50,000 | Sold Out | 0 | $0.00 |
| Q3 2020 | +50,000 | New Buy | 50,000 | $21.66 |
| Q3 2017 | -50,000 | Sold Out | 0 | $0.00 |
| Q2 2017 | +50,000 | New Buy | 50,000 | $12.10 |
Louis Moore Bacon's Cytokinetics Incorporated Investment FAQs
Louis Moore Bacon first purchased Cytokinetics, Incorporated (CYTK) in Q2 2017, acquiring 50,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Cytokinetics, Incorporated (CYTK) for 21 quarters since Q2 2017.
Louis Moore Bacon's largest addition to Cytokinetics, Incorporated (CYTK) was in Q4 2021, adding 100,000 shares worth $4.56 M.
According to the latest 13F filing for Q4 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 25,000 shares of Cytokinetics, Incorporated (CYTK), valued at approximately $1.59 M.
As of the Q4 2025 filing, Cytokinetics, Incorporated (CYTK) represents approximately 0.02% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Cytokinetics, Incorporated (CYTK) was 100,000 shares, as reported at the end of Q4 2021.